Zymeworks (ZYME) Outlines Priorities and Outlook for 2024 and 2025 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Company well-positioned for further progress and broadening of R&D pipelineCash resources of approximately $455 million as of December 31, 2023 Expected cash runway, including proceeds from recent.
PONTE VEDRA, Fla., Jan. 4, 2024 /PRNewswire/ Cadrenal Therapeutics, Inc., , a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant designed to.
Biotech Bonanza: 2024 Biotech Outlook As The Fed Turns Dovish seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
HBM Healthcare Investments AG / Key word: Quarter Results
HBM Healthcare Investments publishes net asset value per share of CHF 225.03 as at 31 December 2023
03-Jan-2024 / 18:15.